-
1.发明授权EXENDIN-4 ANALOGUE PEGYLATED WITH POLYETHYLENE GLYCOL OR DERIVATIVE THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING SAME AS ACTIVE INGREDIENT 有权用聚乙二醇或其衍生物PEG化的EXENDIN-4类似物，其制备方法，以及用于预防或治疗糖尿病的含有活性成分的药物组合物
公开(公告)号：EP2727605B1
公开(公告)日：2018-04-04
申请号：EP12804683.6
申请日：2012-06-28
发明人： LEE, Sung Kwon , KIM, Won Bae , LEE, Seulki , KIM, Tae Hyung
IPC分类号： A61K47/30 , A61K38/22 , A61P3/10 , C07K14/575 , A61K47/60 , A61K9/00 , A61K47/02 , A61K47/26 , A61K9/20 , A61K9/48
CPC分类号： A61K47/02 , A61K9/0019 , A61K9/2018 , A61K9/2059 , A61K9/4858 , A61K9/4866 , A61K38/2278 , A61K47/26 , A61K47/60 , C07K14/57563
摘要： The present disclosure relates to an exendin-4 analogue PEGylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analogue can be increased via the selective PEGylation by using exendin-4 in which a cysteine is introduced into #40 site of the C-terminal, and treatment effect of medications can be increased, so that the exendin-4 analogue can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion.
-
2.发明授权
公开(公告)号：EP2026842B1
公开(公告)日：2016-10-12
申请号：EP07746877.5
申请日：2007-06-12
发明人： LEE, Kang Choon , CHAE, Su Young , YOUN, Yu Seok , KIM, Won Bae , LEE, Sung Kwon
CPC分类号： A61K47/48215 , A61K38/19 , A61K38/191 , A61K47/60 , B01D15/361 , C07K14/52 , C07K14/525 , C07K14/70575 , C07K2319/73 , G01N30/96
摘要： Disclosed herein are an N-terminal modified PEG-TRAIL conjugate and a preparation method and use thereof. The PEG-TAIL conjugate has pharmaceutical activity identical or similar to that of native TRAIL (TNF-related apoptosis-inducing ligand) with extended in vivo half-life and enhanced stability. Compared to native TRAIL, the PEG-TAIL conjugate exhibits high solubility and solution stability, with highly improved pharmacokinetic profiles. Thus, the PEG-TAIL conjugate may be very useful for preventing and treating proliferative diseases and autoimmune diseases.
-
搜索结果
2 条记录 (耗时 0.008 秒)
